177 related articles for article (PubMed ID: 28110996)
1. Fibrolamellar carcinoma: A histologically unique tumor with unique molecular findings.
Graham RP; Torbenson MS
Semin Diagn Pathol; 2017 Mar; 34(2):146-152. PubMed ID: 28110996
[TBL] [Abstract][Full Text] [Related]
2. DNAJB1-PRKACA is specific for fibrolamellar carcinoma.
Graham RP; Jin L; Knutson DL; Kloft-Nelson SM; Greipp PT; Waldburger N; Roessler S; Longerich T; Roberts LR; Oliveira AM; Halling KC; Schirmacher P; Torbenson MS
Mod Pathol; 2015 Jun; 28(6):822-9. PubMed ID: 25698061
[TBL] [Abstract][Full Text] [Related]
3. Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1-PRKACA fusion.
Graham RP; Lackner C; Terracciano L; González-Cantú Y; Maleszewski JJ; Greipp PT; Simon SM; Torbenson MS
Hepatology; 2018 Oct; 68(4):1441-1447. PubMed ID: 29222914
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.
Engelholm LH; Riaz A; Serra D; Dagnæs-Hansen F; Johansen JV; Santoni-Rugiu E; Hansen SH; Niola F; Frödin M
Gastroenterology; 2017 Dec; 153(6):1662-1673.e10. PubMed ID: 28923495
[TBL] [Abstract][Full Text] [Related]
5. Molecular testing for the clinical diagnosis of fibrolamellar carcinoma.
Graham RP; Yeh MM; Lam-Himlin D; Roberts LR; Terracciano L; Cruise MW; Greipp PT; Zreik RT; Jain D; Zaid N; Salaria SN; Jin L; Wang X; Rustin JG; Kerr SE; Sukov WR; Solomon DA; Kakar S; Waterhouse E; Gill RM; Ferrell L; Alves VA; Nart D; Yilmaz F; Roessler S; Longerich T; Schirmacher P; Torbenson MS
Mod Pathol; 2018 Jan; 31(1):141-149. PubMed ID: 28862261
[TBL] [Abstract][Full Text] [Related]
6. DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma.
Vyas M; Hechtman JF; Zhang Y; Benayed R; Yavas A; Askan G; Shia J; Klimstra DS; Basturk O
Mod Pathol; 2020 Apr; 33(4):648-656. PubMed ID: 31676785
[TBL] [Abstract][Full Text] [Related]
7. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.
Hirsch TZ; Negulescu A; Gupta B; Caruso S; Noblet B; Couchy G; Bayard Q; Meunier L; Morcrette G; Scoazec JY; Blanc JF; Amaddeo G; Nault JC; Bioulac-Sage P; Ziol M; Beaufrère A; Paradis V; Calderaro J; Imbeaud S; Zucman-Rossi J
J Hepatol; 2020 May; 72(5):924-936. PubMed ID: 31862487
[TBL] [Abstract][Full Text] [Related]
8. Fibrolamellar Carcinoma: What Is New and Why It Matters.
Graham RP
Surg Pathol Clin; 2018 Jun; 11(2):377-387. PubMed ID: 29751881
[TBL] [Abstract][Full Text] [Related]
9.
Kastenhuber ER; Lalazar G; Houlihan SL; Tschaharganeh DF; Baslan T; Chen CC; Requena D; Tian S; Bosbach B; Wilkinson JE; Simon SM; Lowe SW
Proc Natl Acad Sci U S A; 2017 Dec; 114(50):13076-13084. PubMed ID: 29162699
[TBL] [Abstract][Full Text] [Related]
10. Hepatic adenomas with synchronous or metachronous fibrolamellar carcinomas: both are characterized by LFABP loss.
Graham RP; Terracciano LM; Meves A; Vanderboom PM; Dasari S; Yeh MM; Torbenson MS; Cruise MW
Mod Pathol; 2016 Jun; 29(6):607-15. PubMed ID: 27015136
[TBL] [Abstract][Full Text] [Related]
11. The DNAJB1-PRKACA chimera: Candidate biomarker and therapeutic target for fibrolamellar carcinomas.
Reid LM; Sethupathy P
Hepatology; 2016 Feb; 63(2):662-4. PubMed ID: 26505878
[No Abstract] [Full Text] [Related]
12. A genomic case study of mixed fibrolamellar hepatocellular carcinoma.
Griffith OL; Griffith M; Krysiak K; Magrini V; Ramu A; Skidmore ZL; Kunisaki J; Austin R; McGrath S; Zhang J; Demeter R; Graves T; Eldred JM; Walker J; Larson DE; Maher CA; Lin Y; Chapman W; Mahadevan A; Miksad R; Nasser I; Hanto DW; Mardis ER
Ann Oncol; 2016 Jun; 27(6):1148-1154. PubMed ID: 27029710
[TBL] [Abstract][Full Text] [Related]
13. FGFR1 and FGFR2 in fibrolamellar carcinoma.
Graham RP; Garcia JJ; Greipp PT; Barr Fritcher EG; Kipp BR; Torbenson MS
Histopathology; 2016 Apr; 68(5):686-92. PubMed ID: 26259677
[TBL] [Abstract][Full Text] [Related]
14. Fibrolamellar Hepatocellular Carcinoma: Mechanistic Distinction From Adult Hepatocellular Carcinoma.
Riggle KM; Turnham R; Scott JD; Yeung RS; Riehle KJ
Pediatr Blood Cancer; 2016 Jul; 63(7):1163-7. PubMed ID: 26990031
[TBL] [Abstract][Full Text] [Related]
15. DNAJB1-PRKACA-positive metastatic fibrolamellar carcinoma with unknown primary in a pediatric patient.
Balbeur S; Dumortier A; Mergen J; Libbrecht L; Torbenson M; Boulanger C; de Ville de Goyet M; Van Damme A; Brichard B
Pediatr Blood Cancer; 2020 Feb; 67(2):e28060. PubMed ID: 31736218
[TBL] [Abstract][Full Text] [Related]
16. Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cells.
Oikawa T; Wauthier E; Dinh TA; Selitsky SR; Reyna-Neyra A; Carpino G; Levine R; Cardinale V; Klimstra D; Gaudio E; Alvaro D; Carrasco N; Sethupathy P; Reid LM
Nat Commun; 2015 Oct; 6():8070. PubMed ID: 26437858
[TBL] [Abstract][Full Text] [Related]
17. Advances in fibrolamellar hepatocellular carcinoma: a review.
Lim II; Farber BA; LaQuaglia MP
Eur J Pediatr Surg; 2014 Dec; 24(6):461-6. PubMed ID: 25486412
[TBL] [Abstract][Full Text] [Related]
18. Novel protein kinase cAMP-Activated Catalytic Subunit Alpha (PRKACA) inhibitor shows anti-tumor activity in a fibrolamellar hepatocellular carcinoma model.
Toyota A; Goto M; Miyamoto M; Nagashima Y; Iwasaki S; Komatsu T; Momose T; Yoshida K; Tsukada T; Matsufuji T; Ohno A; Suzuki M; Ubukata O; Kaneta Y
Biochem Biophys Res Commun; 2022 Sep; 621():157-161. PubMed ID: 35839742
[TBL] [Abstract][Full Text] [Related]
19. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma.
Bauer J; Köhler N; Maringer Y; Bucher P; Bilich T; Zwick M; Dicks S; Nelde A; Dubbelaar M; Scheid J; Wacker M; Heitmann JS; Schroeder S; Rieth J; Denk M; Richter M; Klein R; Bonzheim I; Luibrand J; Holzer U; Ebinger M; Brecht IB; Bitzer M; Boerries M; Feucht J; Salih HR; Rammensee HG; Hailfinger S; Walz JS
Nat Commun; 2022 Oct; 13(1):6401. PubMed ID: 36302754
[TBL] [Abstract][Full Text] [Related]
20. Enhanced cAMP-stimulated protein kinase A activity in human fibrolamellar hepatocellular carcinoma.
Riggle KM; Riehle KJ; Kenerson HL; Turnham R; Homma MK; Kazami M; Samelson B; Bauer R; McKnight GS; Scott JD; Yeung RS
Pediatr Res; 2016 Jul; 80(1):110-8. PubMed ID: 27027723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
